Azitra (AZTR) Change in Receivables (2022 - 2026)
Azitra (AZTR) reported Change in Receivables of $4196.0 for Q1 2026, up 1900.86% on a YoY basis from $209.71 in Q1 2025, and up 360.09% quarter-over-quarter from $912.0 in Q4 2025.
Azitra (AZTR) Change in Receivables (2022 - 2026) Analysis & Trends
Azitra has reported Change in Receivables for 5 years, with the latest figure at $4196.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 1900.86% year-over-year to $4196.0; the trailing twelve-month figure through Mar 2026 stood at $5108.0 (up 375.07% YoY), and the FY2025 full-year result was $679.0, up 100.69% from the prior year.
- Change in Receivables for Q1 2026 stood at $4196.0, up from $912.0 in the prior quarter.
- The five-year high for Change in Receivables was $347731.0 in Q2 2023, with the low at -$445120.0 in Q3 2023.
- Historically, Change in Receivables has averaged -$1612.2 across 5 years, with a median of $233.0 in 2024.
- Annual changes were most pronounced in 2023 — Change in Receivables slumped 846.49% — and 2026, when it jumped 1900.86%.
- Azitra's Change in Receivables stood at $97125.0 in 2022, then gained by 1.16% to $98255.0 in 2023, then tumbled by 99.76% to $233.0 in 2024, then soared by 291.42% to $912.0 in 2025, then soared by 360.09% to $4196.0 in 2026.
- The last three Change in Receivables figures came in at $4196.0 (Q1 2026), $912.0 (Q4 2025), and -$233.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | 4,196.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,196.00 |
| Mar 31, 2026 | 4,196.00 |
| Dec 31, 2025 | 912.00 |
| Dec 31, 2025 | 912.00 |
| Mar 31, 2025 | -233.00 |
| Mar 31, 2025 | -233.00 |
| Dec 31, 2024 | 233.00 |
| Dec 31, 2024 | 233.00 |
| Sep 30, 2024 | -1,125.00 |
| Sep 30, 2024 | -1,125.00 |
| Jun 30, 2024 | -732.00 |
| Jun 30, 2024 | -732.00 |
| Mar 31, 2024 | -96,398.00 |
| Mar 31, 2024 | -96,398.00 |
| Dec 31, 2023 | 98,255.00 |
| Dec 31, 2023 | 98,255.00 |
| Sep 30, 2023 | -445,120.00 |
| Sep 30, 2023 | -445,120.00 |
| Jun 30, 2023 | 347,731.00 |
| Jun 30, 2023 | 347,731.00 |